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Abstract
Introduction: Neuromuscular electrical stimulation (NMES) could provide an alternative or adjunct treatment modal-
ity to induce muscle hypertrophy in the hip osteoarthritis population. This preliminary study evaluates the feasibility and
acceptability of NMES to evoke involuntary muscle contractions in adults with advanced hip osteoarthritis.
Methods: Thirteen adults with moderate-to-severe hip osteoarthritis and fifteen healthy, older adults were invited to a
lab-based testing session. NMES was applied unilaterally to the knee extensors and hip abductors for one continuous,
five-minute testing session. Data were collected on device acceptability, tolerability and muscle contractile force, and
compared between groups.
Results: Electrical stimulation of the knee extensors elicited a visible muscular contraction in 11 participants (85%) with
hip osteoarthritis and 15 controls (100%) at an intensity acceptable to the participant. Electrical stimulation of the hip
abductors elicited a muscular contraction in eight participants (62%) with osteoarthritis, and ten controls (67%). Muscle
contractile force, pain, discomfort and acceptability did not differ between groups, however NMES of the knee exten-
sors was favoured across all measures of assessment when compared to the hip abductors.
Conclusions: Electrical stimulation of the knee extensors may be a feasible and acceptable treatment modality to
address muscle atrophy in adults with advanced hip osteoarthritis.
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Background
Bilateral lower-limb muscle weakness and fatigue are
features of individuals with advanced hip osteoarthri-
tis,1–6 which can lead to functional disability and an
increased risk of further morbidity and mortality.7,8
To counteract musculoskeletal impairment, local
muscle strengthening and aerobic exercise are recom-
mended irrespective of age, comorbidity, pain severity
or disability.9–12 Likewise, when progression of the dis-
ease leads to consideration for total hip replacement
surgery, preoperative exercise programmes are pro-
posed as a potential method to expedite recovery
time.13–15 Nonetheless, some patients choose to avoid
traditional exercise due to fear of causing joint damage
or exacerbating pain,16–20 and the evidence supporting
physiotherapy prior to hip replacement for improving
function is equivocal.13
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Neuromuscular electrical stimulation (NMES) is an
alternative treatment that can counteract muscle weak-
ness in adults with advanced progressive diseases; and
has long been used to preserve or restore skeletal
muscle mass and function during and after a period
of disuse due to injury, surgery, or illness.21–23 NMES
involves the application of electrical impulses to skele-
tal muscles, by means of surface electrodes placed over
the muscle belly, with the ultimate goal to evoke visible
muscular contractions.22 The activation pattern of
these contractions differs substantially from that of
voluntary contractions, whereby motor units are
recruited in a non-selective, spatially fixed, and tempo-
rally synchronous pattern.24 Whilst the force con-
tracted through muscle stimulation is not greater than
that of voluntary isometric contractions, it can be used
where the pathology prevents voluntary exercise at
either sufficient intensity or duration to be effective,
with the end goal of moving onto voluntary exercise
when strength and tolerance permits.25–27 In addition,
it can be used as an adjunct modality to enhance the
strengthening effects of an existing rehabilitation pro-
gramme, or support patients with muscle weakness
who cannot tolerate high-intensity exercise or a high-
volume of low-intensity exercise.21
Despite the evidence supporting electrical stimula-
tion as a method to improve muscle strength, voluntary
activation and functional recovery, NMES therapy
remains clinically underutilised in orthopaedic prac-
tice.22,28,29 Moreover, whilst there has been an expan-
sion of research in the area of knee osteoarthritis and
NMES for strength improvements, investigations
within hip osteoarthritis are sparse.23,30 NMES may
offer a promising alternative approach to counteract
muscle inhibition and minimise atrophy and thus
restore normal muscle function more effectively than
voluntary exercise alone. This preliminary study aims
to investigate the feasibility and patient acceptability of
using NMES as a treatment option to counteract
muscle weakness amongst adults with advanced hip
osteoarthritis. Data are compared to healthy adults,
to observe any differences in response to NMES that
may be attributable to hip joint pathology.
Methods
Participants
This is an observational case-control study recruiting
two study groups: i) adults with a clinical diagnosis of
unilateral or bilateral hip osteoarthritis and ii) healthy
adults aged over 60 years (control group) between 12th
November 2019 and 15th March 2020. Participants
were recruited from the local area through online
advertisement and email recruitment sent to local
organisations. Sixty years was chosen as the minimum
age for the control group as osteoarthritis of the hip
increases between the ages of 45 and 75,31 and the aver-
age age for total hip replacement surgery is 68.0
11.4 years.32 Participants were included in the hip oste-
oarthritis group if they had: i) received a clinical diag-
nosis of hip osteoarthritis from their general
practitioner, an orthopaedic specialist or a physiother-
apist; ii) presented with chronic joint pain for at least
three months; iii) had an Oxford Hip score33 of less
than 40; and iv) were not on the waiting list for total
hip replacement surgery. Participants were included in
the control group if they were over 60 years old with no
significant musculoskeletal comorbidities or neurolog-
ical diseases. Exclusion criterion for both groups
included: i) neurological disease affecting walking abil-
ity; ii) rheumatoid arthritis; iii) fitted with a pacemaker
or other active medical implant; iv) uncontrolled epi-
lepsy; v) sepsis or osteomyelitis; vi) known metastatic
tumour involving the hip; vii) poor skin condition that
prevented the use of self-adhesive electrodes; viii) not
physically able to complete the testing protocol or ix)
not able to provide informed consent. The experimen-
tal protocol was approved by the institutional ethics
committee on 5th September 2019. In keeping with
good practice, the ethical principles for medical
research outlined in the Declaration of Helsinki were
followed.34 The STROBE (Strengthening the
Reporting of Observational Studies in Epidemiology)
statement for the reporting of cross-sectional studies
was used to guide the reporting of this study.35
Electrical muscle stimulation device
The NMES device chosen for this study was the
Orthopaedic Microstim 2V2 neuromuscular stimulator
(developed by Odstock Medical Ltd, Salisbury, UK).
The device has been developed for general orthopaedic
use, and for following joint replacement surgery, and
consists of a stimulator box with two leads which are
connected to two multiple use self-adhesive electrodes.
It includes specific programmes to target muscle con-
ditioning, endurance or power, in addition to pro-
grammes aimed at improving venous return and
preventing thrombosis and pain relief modes. The pro-
gramme chosen for this study was mode 0 (“set-up”)
which is most appropriate when first evaluating elec-
trode positioning and stimulation intensity. Whilst it is
more common for an intermittent stimulation to be
delivered within clinical practice, this mode delivers a
continuous stimulation output, which is useful for
determining individual responses to NMES with a con-
trolled approach. The mode delivers a frequency of
40Hz and a pulse duration of 300ms.
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Procedures
Participants were invited to attend a laboratory-based
testing session. Participants were shown the NMES
device and given instructions on how to operate it.
The device was fitted by a researcher to the knee exten-
sors and hip abductors of the participants. These
muscle groups were chosen due to their importance
for activities of daily living,36–38 and susceptibility to
weakness and atrophy in hip osteoarthritis.1,2,39 NMES
was applied unilaterally, to the affected limb of the
participants with hip osteoarthritis, and to the right
limb of the control group. For participants with bilat-
eral hip osteoarthritis, NMES was applied to the more
severely affected limb. To stimulate the knee extensors
(the quadriceps femoris muscle group), two PALS plat-
inum 70mm (2.75”) round electrodes were positioned
on the vastus lateralis and vastus medialis, in line with
manufacturer instructions (Figure 1). For the hip
abductors (gluteus medius, gluteus minimus and
tensor faciae latae), two 70mm round electrodes were
placed over the proximal and distal components of the
gluteus medius (Figure 2). Once the device was fitted,
the participant operated the device independently for a
period of around five minutes. Data were collected on
device acceptability, tolerability and muscle contractile
force and compared between groups to observe any
differences in response to NMES in participants with
hip osteoarthritis and healthy, age-matched controls.
Variables
Age, weight, height and medical history were recorded
from all participants. Affected side(s), duration of
symptoms and the use of analgesia for pain relief
were recorded from the participants in the hip osteoar-
thritis group. The subjective severity of hip pain when
weight bearing was rated using the Numeric Pain
Rating (NPR) scale (range 0–10 with 0 depicting no
pain and 10 representing unbearable pain) and the
severity of symptoms were quantified using the
Oxford Hip Score.33
Tolerability. Once the device was fitted, participants
independently operated the device and were instructed
to gradually increase the current intensity, starting at
Figure 1. Electrode positioning during electrical stimulation of
the knee extensors.
Figure 2. Electrode positioning during electrical stimulation of
the hip abductors.
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10mA, until a visible involuntary muscle contraction
was produced. If it was not possible to produce an
involuntary muscle contraction, the participant was
asked to increase the current intensity to the maximum
tolerated for a period of around five minutes. Each
mark on the stimulator corresponded to approximately
10mA. The current intensity required to elicit an invol-
untary muscle contraction, or maximum current inten-
sity tolerated, was recorded as a measure of device
tolerability.
Pain and discomfort. Pain and discomfort were also used
as measures of device tolerability. Pain during muscle
contraction was recorded using a Numeric Rating Scale
(NRS), with a score of zero describing no pain at all,
and a score of 10 depicting the worst pain imaginable.
If no visible muscle contraction was elicited, pain was
recorded during the maximum stimulation intensity
tolerated by the participant. Discomfort was assessed
through the administration of a Likert Scale question-
naire that has previously been used to quantify discom-
fort associated with NMES.40,41 Participants were
asked to score their discomfort in comparison to a
blood pressure cuff inflated on the arm on a scale of
one to five, with a score one depicting no discomfort
and a score of five describing severe discomfort.
Muscle contractile force. To evaluate if the current inten-
sity tolerated was sufficient to evoke an involuntary
muscle contraction, and the relative feasibility of the
device within rehabilitation, the strength of muscle con-
traction produced by NMES was scored through visual
inspection and the definitions used in the Medical
Research Council’s scale (MRC scale) of muscle
power.42 Although it does not measure strength itself,
the MRC scale is the most commonly accepted method
of evaluating volitional muscle activation and has
proven to be reliable and accurate for clinical assess-
ment in weak muscles.43
Once an involuntary muscle contraction was pro-
duced, or the participant had reached the maximum
intensity of stimulation tolerable, the muscle contrac-
tion was graded independently by one researcher using
the descriptions in Table 1. For example, if the NMES
device could not activate a muscle contraction (no trace
or flicker), the investigator would award a score of
zero. If a flicker or trace of muscle activation was
observed, a score of one was awarded. During knee
extensor stimulation, the participant was seated on
the end of a plinth, other than during the assessment
of MRC grade 2. For this assessment, the participant
was side lying with their leg supported. For hip
abduction, the participant was side lying, with their
test side up.
Acceptability. At the end of the testing session, partici-
pants were asked if they would consider using the
device in a treatment routine (yes/no answer), and to
provide any other comments or opinions about the
NMES device.
Sample size and statistical methods
A formal sample size calculation was not considered
appropriate given the study design.44 Following recom-
mendations for the design of usability studies in med-
ical devices,45 a sample size of 15 participants per group
was sought. Data were compared between groups to
observe any differences in response to NMES that
may be a result of hip joint pathology.
All data were analysed using IBM SPSS Statistics
version 26 (SPSS Inc., Chicago, USA), with the signif-
icance level set at p< 0.05. Normality of the numerical
data were analysed using a Shapiro-Wilk test. If both
samples passed the preliminary normality test, an inde-
pendent samples t test was conducted.46 The current
intensity data were not normally distributed, and
hence, a Mann-Whitney U test was conducted to com-
pare tolerability between groups. Mean (standard devi-
ation) and median (interquartile range (IQR)) were
used to describe normally and non-normally distribut-
ed data, respectively.47 Categorical data were analysed
using a Fisher’s exact test (two variables) or a Pearson’s
chi-squared (more than two variables) and results were
presented as percentages. Participant feedback on
acceptability was categorised into key themes and
reported using a descriptive analysis.
Results
Fifty-eight individuals volunteered to take part in the
study (Figure 3). During the initial telephone consulta-
tion, 16 volunteers did not meet the inclusion criteria
due to: musculoskeletal comorbidity (n¼ 6); prior joint
Table 1. MRC scale of muscle power, used with permission of
the Medical Research Council.
Score Description
0 No muscle activation
1 Trace muscle activation, such as a twitch, without
achieving full range of motion
2 Muscle activation without gravity resistance,
achieving full range of motion
3 Muscle activation against gravity, full range of
motion
4 Muscle activation against some resistance, full
range of motion
5 Muscle activation against examiner’s full
resistance, full range of motion
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replacement (n¼ 5); hip pain but no clinical diagnosis
of osteoarthritis (n¼ 2); cardiovascular comorbidity
(n¼ 1), fitted with a pacemaker (n¼ 1); and listed for
total hip replacement surgery (n¼ 1), and were exclud-
ed from the study. Six participants declined participa-
tion due to travel or time commitments. A total of 36
were invited to attend the testing session. Two partic-
ipants in the control group were excluded during the
eligibility assessment due to knee pathology not previ-
ously disclosed. A further six participants were unable
to attend the testing session due to the COVID-19 pan-
demic and the Government advice to close higher edu-
cation institutes. Hence, the study was prematurely
closed on 15th March 2020. This analysis includes 28
participants who were recruited prior to the pandemic
(hip osteoarthritis, n¼ 13; control group, n¼ 15).
There were no differences between groups in terms
of age (p¼ 0.39) or gender distribution (p¼ 1.00). The
hip osteoarthritis group had a significantly higher BMI
than the control group (p¼ 0.03). Participants with hip
osteoarthritis group had a mean Oxford Hip Score of
28 7.81 (range: 18–39), suggesting moderate-to-severe
hip osteoarthritis.33 The mean duration of symptoms
was 4.04 3.17 years (range: 6months–10 years) and
mean VAS pain on weight bearing was 5.31 1.49
(range 3–8) (Table 2). Six participants were not
taking any analgesics, four were taking paracetamol
or ibuprofen when required, one was taking codeine
and paracetamol, one was taking the maximum dose
of paracetamol, and one participant was taking diahy-
drocodine in addition to cod liver oil.
Tolerability
All participants were comfortable with the NMES sen-
sation and tolerated electrical stimulation of the knee
extensors and hip abductors for the testing period. The
median current intensity tolerated during knee extensor
stimulation in the osteoarthritis group was 45mA
(IQR: 40–50), and 47mA (IQR 40–50) in the control
group. The median current intensity tolerated during
Potentially eligible  
n = 58 
Confirmed eligible 
n = 28 
Examined for eligibility 
n = 30 
Included in study 
n = 28 
Hip osteoarthritis 
n = 13 
Healthy controls  
n = 15 
Excluded at baseline 
n = 2 
Knee pathology, n = 2 
Data analysed 
Hip osteoarthritis, n = 13 
Data analysed 
Healthy controls, n = 15 
Invited to participate 
n = 36 
Unable to participate due to COVID-19, 
n = 6 
Excluded via telephone consultation 
n = 22 
Clinically inappropriate, n = 16 
   Musculoskeletal comorbidity, n = 6 
   Prior joint replacement, n = 5 
   No clinical diagnosis of hip OA, n = 2    
   Cardiovascular comorbidity, n = 1 
   Fitted with a pacemaker, n = 1 
   Listed for total hip replacement, n = 1 
Declined participation, n = 6 
Figure 3. Participant recruitment through the study.
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hip abductor stimulation in the osteoarthritis group
was 45mA (IQR: 40–50) and 40mA (IQR: 40–50) in
the control group. Self-selected maximum stimulation
intensity did not differ between groups during electrical
stimulation of the knee extensors (p¼ 0.89) or hip
abductors (p¼ 0.45).
Pain and discomfort
Pain during electrical stimulation was reported by one
participant from each group during stimulation of the
knee extensors. Pain was scored as 1/10 by the partic-
ipant with osteoarthritis, and 4/10 by the participant in
the control group. Pain during electrical stimulation of
the hip abductors was reported by four participants
(31%) in the osteoarthritis group (range: 2–7), and by
three participants (20%) in the control group
(range: 3–7). No discomfort was reported by the oste-
oarthritis group during stimulation of the knee
extensors. Discomfort was more commonly reported
during stimulation of the hip abductors (Table 3).
There were no differences in discomfort between the
osteoarthritis and control group during electrical stim-
ulation of the knee extensors (p¼ 0.13) or hip abduc-
tors (p¼ 0.72).
Muscle contractile force
Neuromuscular electrical stimulation of the knee exten-
sors evoked an involuntary muscular contraction in 11
participants (85%) in the hip osteoarthritis group and
15 participants (100%) in the control group, at a stim-
ulation intensity acceptable to the participant.
Electrical stimulation of the hip abductors evoked an
involuntary muscular contraction in eight participants
(62%) in the osteoarthritis group, and ten participants
(67%) in the control group. Muscle contractile force, as
measured by the MRC scale for muscle power, was not
significantly different between study groups during
stimulation of the knee extensors (p¼ 0.29) or hip
abductors (p¼ 1.00). However, muscle contractile
force was greater in the knee extensors, when compared
to the hip abductors, in both study groups (Table 4).
Acceptability
All participants in both study groups reported that they
would consider using electrical stimulation of the knee
extensors and hip abductors in a treatment routine.
Two participants in the osteoarthritis group and two
in the control group expressed concern with the process
of independently locating the muscles and placing elec-
trodes. Two participants in the osteoarthritis group
reported pain relief during stimulation of the hip
abductors. Five participants in the control group said
they would not have been able to tolerate a current
higher than their self-selected maximum. One partici-
pant in the control group referred to the device as dis-
tracting rather than uncomfortable, and one described
it as a useful alternative or adjunct to conventional
exercise.










Age (years) 75 7.69 72 4.95 75 7.30 72 6.42
Males, n (%) 4 (36%) 1 (50%) 5 (38%) 5 (33%)
Height (m) 1.68 0.08 1.70 9.90 1.68 0.08 1.68 0.12
Weight (kg) 83.0 18.29 91.00 4.24 84.23 17.01 71.85 14.89
BMI (kg/m2) 29 6 32 2 30 6 25 4
Oxford Hip Score 27 7 34 5 28 7 N/A
Pain (VAS) 5.79 1.62 5.5 0.71 5.31 1.49 N/A
Duration of symptoms (years) 3.68 2.82 6.0 5.66 4.04 3.17 N/A
Table 3. Discomfort experienced during electrical stimulation of the knee extensors and hip abductors in adults with hip
osteoarthritis, compared to healthy older adults.
Knee extensors Hip abductors
Discomfort Osteoarthritis Control Sig (2-tailed) Osteoarthritis Control Sig (2-tailed)
Minimal discomfort 13 (100%) 11 (73%) p¼ 0.13 8 (62%) 11 (73%) p¼ 0.72
Mild discomfort 0 3 (20%) 2 (15%) 1 (7%)
Moderate discomfort 0 1 (7%) 3 (23%) 3 (20%)
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Discussion
Electrical muscle stimulation has a long-established
place in therapy practice48 and has been shown to pre-
serve or restore muscle mass and aspects of neuromus-
cular function in a range of musculoskeletal conditions,
including both acute injuries and chronic conditions.23
Nonetheless, NMES therapy remains clinically underu-
tilised in the hip osteoarthritis population.30 The slow
transition of NMES into clinical practice has been
attributed to a lack of guidelines on stimulation param-
eters, uncertainty regarding the feasibility of stimula-
tion for inducing strength gains, and concerns of
intolerance in patients particularly sensitive to electri-
cal stimulation.22 A key component of assessing the
feasibility of clinical interventions is patient acceptabil-
ity, which relates to how the intended recipients react
to the intervention.49 In this preliminary study, the fea-
sibility and acceptability of the NMES device were
measured in a cohort of participants with advanced
hip osteoarthritis, and compared to a cohort of
healthy, age-matched controls, to observe any differ-
ences in stimulation response attributable to hip joint
pathology.
Neuromuscular electrical stimulation of the knee
extensors elicited a visible muscular contraction in 11
participants (85%) in the hip osteoarthritis group and
15 participants (100%) in the control group, at a stim-
ulation intensity acceptable to the participant.
Electrical stimulation of the hip abductors elicited a
muscular contraction in eight participants (62%) in
the osteoarthritis group, and ten participants (67%)
in the control group. Muscle contractile force, pain,
discomfort and acceptability did not differ between
groups, however electrical stimulation of the knee
extensors was favoured across all measures of assess-
ment when compared to the hip abductors in both
groups. These findings suggest that electrical stimula-
tion of the knee extensors may be an efficacious and
acceptable treatment modality to address muscle weak-
ness in the hip osteoarthritis population. These findings
are perhaps not surprising, given the evidence for
NMES alone or combined with exercise for quadriceps
strengthening in patients with osteoarthritis of the
knee,50 but nonetheless provide important information
for future research endeavours in this area.
Importantly, no differences were observed in muscle
contractile force between the two study groups during
stimulation of the knee extensors or hip abductors.
NMES involves the application of electrical impulses
to skeletal muscles, by means of surface electrodes
placed over the muscle belly, with the ultimate goal
to evoke visible muscle contractions.22 The basic theo-
retical premise of electrical muscle stimulation is that if
the peripheral nerve can be stimulated, the resulting
excitation impulse will be transmitted along the nerve
to the motor endplates in the muscle, producing a
muscle contraction, which will have an eventual effect
on muscle hypertrophy and strength.51 Aerobic exer-
cise and local muscle strengthening are recommended
as core components in the management of hip osteoar-
thritis,9–11 however, voluntary exercise may be inhib-
ited by pain during joint loading. During electrical
stimulation of the knee extensors, it was possible to
achieve muscle activation and full range of motion in
the majority of participants, with only two reports of
pain. Clinically, these findings are important for
patients who cannot perform conventional, voluntary
exercise at either sufficient intensity or duration to be
effective.
Interestingly, it was not possible to achieve a muscle
contraction at a tolerable level of stimulation of the hip
abductors in over one third of each study group, and
the most powerful contraction elicited, as graded by the
MRC scale, was a trace muscle activation. These find-
ings may be explained by a higher percentage of fatty
infiltration in the gluteal muscles when compared to the
quadriceps and the substantial decrease in contractile
tissues of the gluteal muscles evident in patients with
hip osteoarthritis.52–55 Due to the high resistivity of
subcutaneous fat tissue, higher stimulus currents are
required to evoke muscle contractions where there is
higher skeletal muscle fat infiltration, which can lead
to patient discomfort.56 These predictions are sup-
ported by the assessment of tolerability, whereby
both pain and discomfort were more frequently
Table 4. Muscle contractile force during unilateral electrical stimulation of the knee extensors and hip abductors in adults with hip
osteoarthritis, compared to healthy older adults.
Knee extensors Hip abductors
MRC grade Osteoarthritis Control Sig (2-tailed) Osteoarthritis Control Sig (2-tailed)
0 No muscle activation 2 (15%) 0 p¼ 0.29 5 (39%) 5 (33%) p¼ 1.00
1 Trace muscle activation 1 (8%) 4 (27%) 8 (62%) 10 (67%)
2 Activation without gravity resistance 9 (69%) 10 (67%) 0 0
3 Activation against gravity 1 (8%) 1 (7%) 0 0
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reported in both study groups during electrical stimu-
lation of the hip abductors when compared to the knee
extensors. From these findings, we can anticipate that
electrical stimulation of the knee extensors will be more
acceptable than electrical stimulation of the hip abduc-
tors in the hip osteoarthritis population. These findings
are promising given the success of NMES applied to
the knee extensors in individuals with knee osteoarthri-
tis, whereby electrical stimulation has been shown to
increase strength, train endurance, minimise atrophy,
reduce pain and increase range of motion.23,57 Future
research is required to examine the effectiveness of
NMES for improving knee extensor strength and
endurance in the hip osteoarthritis population.
Limitations
A clear limitation of this study is the failure to meet the
sample size sought due to a global pandemic and the
premature completion of data collection. Participants
were encouraged to answer the questions on the NMES
device honestly and accurately. Nonetheless, we recog-
nise an element of response bias may exist in the feed-
back of the device, whereby the participants felt they
should report a favourable opinion.58 It should be
acknowledged that the size of the electrode used with
electrical stimulation can markedly affect the stimula-
tion response, and that choosing a larger electrode may
have improved the strength of contraction. In addition,
tolerance to stimulation can increase with repeated
use,59 and thus a higher current intensity may be
achieved over time. The continuous contraction
length used in this study may be less comfortable
than the intermittent stimulation used most with
NMES. Finally, the MRC grade is a subjective mea-
sure, and only quantifies the category of contraction
strength, not strength itself.43
Conclusions
Neuromuscular electrical stimulation of the knee exten-
sors may be a feasible treatment method to address
muscle weakness in the hip osteoarthritis population.
NMES was well-tolerated and acceptable to partici-
pants and may serve as an alternative or adjunct treat-
ment to improve muscle function for those who have
difficulty participating in voluntary exercise. Future
research evaluating the effectiveness of NMES for
improving strength, endurance or minimising atrophy
is required to progress these findings.
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